PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations

NCT01089998 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Diagnostic Imaging

Interventions

DRUG: BAY86-9596
DRUG: BAY86-9596
DRUG: BAY86-9596
DRUG: Fludeoxyglucose (18F)-IBA

Sponsor

Life Molecular Imaging SA